You are here

  • Home
  • Archive
  • Volume 80, Issue 9
  • Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Citation Tools

Article menu
Download PDFPDF
Rheumatoid arthritis
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sparks JA, Wallace ZS, Seet AM COVID-19 Global Rheumatology Alliance, et al
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Annals of the Rheumatic Diseases 2021;80:1137-1146.